Pharsight

Tyzeka patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6395716 NOVARTIS β-L-2′-deoxy-nucleosides for the treatment of hepatitis B
Aug, 2019

(4 years ago)

US7795238 NOVARTIS β-L-2′-deoxy-nucleosides for the treatment of hepatitis B
Aug, 2019

(4 years ago)

US6566344 NOVARTIS β-L-2′-deoxy-nucleosides for the treatment of hepatitis B
Aug, 2019

(4 years ago)

US6444652 NOVARTIS β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
Aug, 2019

(4 years ago)

US6569837 NOVARTIS β-L-2′-deoxy pyrimidine nucleosides for the treatment of hepatitis B
Oct, 2020

(3 years ago)

US7858594 NOVARTIS Crystalline and amorphous forms of beta-L-2′-deoxythymidine
Sep, 2023

(9 months ago)

US7589079 NOVARTIS Crystalline and amorphous forms of beta-L-2′-deoxythymidine
Sep, 2023

(9 months ago)

Tyzeka is owned by Novartis.

Tyzeka contains Telbivudine.

Tyzeka has a total of 7 drug patents out of which 7 drug patents have expired.

Expired drug patents of Tyzeka are:

  • US6395716
  • US7795238
  • US6566344
  • US6444652
  • US6569837
  • US7858594
  • US7589079

Tyzeka was authorised for market use on 25 October, 2006.

Tyzeka is available in solution;oral, tablet;oral dosage forms.

Tyzeka can be used as treatment of chronic hepatitis b in adult patients, treatment of chronic hepatitis b in adult patients with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (alt or ast) or histologically active disease.

Drug patent challenges can be filed against Tyzeka from 25 October, 2010.

The generics of Tyzeka are possible to be released after 11 September, 2023.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 25, 2011
M(M-124) Jan 28, 2016

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using TELBIVUDINE ingredient

NCE-1 date: 25 October, 2010

Market Authorisation Date: 25 October, 2006

Treatment: Treatment of chronic hepatitis b in adult patients; Treatment of chronic hepatitis b in adult patients with evidence of viral replication and either evidence of persistent elevations in serum aminotra...

Dosage: TABLET;ORAL; SOLUTION;ORAL

More Information on Dosage

TYZEKA family patents

Family Patents